ABSTRACT
The angiotensin II receptors AT1R and AT2R serve as key components of the renin-angiotensin-aldosterone system. AT1R has a central role in the regulation of blood pressure, but the function of AT2R is unclear and it has a variety of reported effects. To identify the mechanisms that underlie the differences in function and ligand selectivity between these receptors, here we report crystal structures of human AT2R bound to an AT2R-selective ligand and to an AT1R/AT2R dual ligand, capturing the receptor in an active-like conformation. Unexpectedly, helix VIII was found in a non-canonical position, stabilizing the active-like state, but at the same time preventing the recruitment of G proteins or ß-arrestins, in agreement with the lack of signalling responses in standard cellular assays. Structure-activity relationship, docking and mutagenesis studies revealed the crucial interactions for ligand binding and selectivity. Our results thus provide insights into the structural basis of the distinct functions of the angiotensin receptors, and may guide the design of new selective ligands.
Subject(s)
Models, Molecular , Receptor, Angiotensin, Type 2/chemistry , Receptor, Angiotensin, Type 2/metabolism , Angiotensin II Type 2 Receptor Blockers/chemistry , Angiotensin II Type 2 Receptor Blockers/metabolism , Binding Sites/genetics , Crystallography, X-Ray , Drug Design , Heterotrimeric GTP-Binding Proteins/chemistry , Heterotrimeric GTP-Binding Proteins/metabolism , Humans , Ligands , Molecular Docking Simulation , Mutation , Protein Binding , Protein Conformation , Receptor, Angiotensin, Type 1/chemistry , Receptor, Angiotensin, Type 1/metabolism , Receptor, Angiotensin, Type 2/agonists , Receptor, Angiotensin, Type 2/genetics , Signal Transduction , Structure-Activity Relationship , Substrate Specificity/genetics , beta-Arrestins/metabolismABSTRACT
Reported herein are a series of reverse indoles that represent novel non-steroidal mineralocorticoid receptor (MR) antagonists. The key structure-activity relationships (SAR) are presented below. This reverse indole series is exemplified by a compound that demonstrated efficacy in an acute natriuresis rodent model comparable to marketed MR antagonists, spironolactone and eplerenone.
Subject(s)
Drug Discovery , Indoles/pharmacology , Mineralocorticoid Receptor Antagonists/pharmacology , Receptors, Mineralocorticoid/metabolism , Dose-Response Relationship, Drug , Humans , Indoles/chemical synthesis , Indoles/chemistry , Mineralocorticoid Receptor Antagonists/chemical synthesis , Mineralocorticoid Receptor Antagonists/chemistry , Molecular Structure , Structure-Activity RelationshipABSTRACT
Bioisosteres are integral components of modern pharmaceutical research that allow structural optimization to maximize in vivo efficacy and minimize adverse effects by selectively modifying pharmacodynamic, pharmacokinetic and physicochemical properties. A recent medicinal chemistry campaign focused on identifying small molecule inhibitors of prolylcarboxypeptidase (PrCP) initiated an investigation into the use of pyrazoles as bioisosteres for amides. The results indicate that pyrazoles are suitable bioisosteric replacements of amide functional groups. The study is an example of managing bioisosteric replacement by incorporating subsequent structural modifications to maintain potency against the selected target. A heuristic model for an embedded pharmacophore is also described.
Subject(s)
Carboxypeptidases/antagonists & inhibitors , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Pyrazoles/pharmacology , Animals , Carboxypeptidases/metabolism , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemical synthesis , Humans , Mice , Molecular Structure , Pyrazoles/chemical synthesis , Pyrazoles/chemistry , Structure-Activity RelationshipABSTRACT
Novel potent and selective mineralocorticoid receptor antagonists were identified, utilizing heterocyclic amide replacements in the oxazolidinedione series. Structure-activity relationship (SAR) efforts focused on improving lipophilic ligand efficiency (LLE) while maintaining nuclear hormone receptor selectivity and reasonable pharmacokinetic profiles.
Subject(s)
Amides/chemistry , Heterocyclic Compounds/chemistry , Mineralocorticoid Receptor Antagonists/pharmacology , Oxazoles/pharmacology , Receptors, Mineralocorticoid/metabolism , Animals , Dose-Response Relationship, Drug , Humans , Microsomes, Liver , Mineralocorticoid Receptor Antagonists/chemical synthesis , Mineralocorticoid Receptor Antagonists/chemistry , Molecular Structure , Oxazoles/chemical synthesis , Oxazoles/chemistry , Rats , Structure-Activity RelationshipABSTRACT
Novel oxazolidinedione analogs were discovered as potent and selective mineralocorticoid receptor (MR) antagonists. Structure-activity relationship (SAR) studies were focused on improving the potency and microsomal stability. Selected compounds demonstrated excellent MR activity, reasonable nuclear hormone receptor selectivity, and acceptable rat pharmacokinetics.
Subject(s)
Mineralocorticoid Receptor Antagonists/chemistry , Oxazoles/chemistry , Receptors, Mineralocorticoid/metabolism , Animals , Binding Sites , Drug Evaluation, Preclinical , Half-Life , Humans , Microsomes/metabolism , Mineralocorticoid Receptor Antagonists/chemical synthesis , Mineralocorticoid Receptor Antagonists/pharmacokinetics , Molecular Docking Simulation , Oxazoles/chemical synthesis , Oxazoles/pharmacokinetics , Protein Structure, Tertiary , Rats , Receptors, Mineralocorticoid/chemistry , Structure-Activity RelationshipABSTRACT
In an effort to understand the origin of blood-pressure lowering effects observed in recent clinical trials with 11ß-HSD1 inhibitors, we examined a set of 11ß-HSD1 inhibitors in a series of relevant in vitro and in vivo assays. Select 11ß-HSD1 inhibitors reduced blood pressure in our preclinical models but most or all of the blood pressure lowering may be mediated by a 11ß-HSD1 independent pathway.
Subject(s)
11-beta-Hydroxysteroid Dehydrogenase Type 1/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Hypertension/drug therapy , Hypertension/enzymology , Triazoles/pharmacology , Animals , Humans , Mice , Mice, Knockout , Rats , Rats, Inbred SHRABSTRACT
The synthesis, SAR, binding affinities and pharmacokinetic profiles are described for a series of cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors discovered by high throughput screening. Compounds show high levels of ex vivo target engagement in mouse plasma 20 h post oral dose.
Subject(s)
Carboxypeptidases/antagonists & inhibitors , Cyclohexanes/chemistry , Cyclohexanes/pharmacology , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Animals , Cyclohexanes/pharmacokinetics , Drug Discovery , Male , Mice , Mice, Inbred C57BL , Molecular Structure , Obesity/drug therapy , Structure-Activity RelationshipABSTRACT
The generation of peptides presented by MHC class I molecules requires the proteolytic activity of the proteasome and/or other peptidases. The processing of a short vaccinia virus-encoded antigen can take place by a proteasome-independent pathway involving initiator caspase-5 and -10, which generate antigenic peptides recognized by CD8(+) T lymphocytes. In the present study, comparing single versus double enzyme digestions by mass spectrometry analysis, both qualitative and quantitative differences in the products obtained were identified. These in vitro data suggest that each enzyme can use the degradation products of the other as substrate for new cleavages, indicating concerted endoproteolytic activity of caspase-5 and -10.
Subject(s)
Antigens, Viral/chemistry , Antigens/metabolism , Caspase 10/chemistry , Caspases/chemistry , Amino Acid Sequence , CD8-Positive T-Lymphocytes/metabolism , Enzyme Inhibitors/pharmacology , Epitopes/chemistry , Humans , Mass Spectrometry/methods , Molecular Sequence Data , Peptides/chemistryABSTRACT
Novel prolylcarboxypeptidase (PrCP) inhibitors with nanomolar IC(50) values were prepared by replacing the previously described dichlorobenzimidazole-substituted pyrrolidine amides with a variety of substituted benzylamine amides. In contrast to prior series, the compounds demonstrated minimal inhibition shift in whole serum and minimal recognition by P-glycoprotein (P-gp) efflux transporters. The compounds were also cell permeable and demonstrated in vivo brain exposure. The in vivo effect of compound (S)-6e on weight loss in an established diet-induced obesity (eDIO) mouse model was studied.
Subject(s)
Benzimidazoles/pharmacology , Brain/metabolism , Carboxypeptidases/antagonists & inhibitors , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP Binding Cassette Transporter, Subfamily B/metabolism , Amides/chemistry , Animals , Biological Transport , Body Weight , Brain/drug effects , Disease Models, Animal , Humans , Inhibitory Concentration 50 , Mice , Models, Chemical , Obesity/drug therapy , Pyrrolidines/chemistry , Time FactorsABSTRACT
Efforts to modify the central proline portion of lead compound 4 lead to the discovery of novel prolylcarboxypeptidase (PrCP) inhibitors. Especially, replacement with alanine afforded compound 19 displaying more potent human and mouse PrCP inhibitory activity than 4 and an overall comparable profile.
Subject(s)
Alanine/chemistry , Carboxypeptidases/antagonists & inhibitors , Drug Discovery , Alanine/pharmacology , Animals , Enzyme Activation/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Humans , Inhibitory Concentration 50 , Mice , Molecular Structure , Structure-Activity RelationshipABSTRACT
A series of benzodihydroisofurans were discovered as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase (PrCP) inhibitors. The structure-activity relationship (SAR) is focused on improving PrCP activity and metabolic stability, and reducing plasma protein binding. In the established diet-induced obese (eDIO) mouse model, compound ent-3a displayed target engagement both in plasma and in brain. However, this compound failed to induce significant body weight loss in eDIO mice in a five-day study.
Subject(s)
Carboxypeptidases/antagonists & inhibitors , Drug Discovery , Enzyme Inhibitors/pharmacology , Furans/chemistry , Furans/pharmacology , Animals , Cells, Cultured , Disease Models, Animal , Drug Stability , Enzyme Activation/drug effects , Furans/chemical synthesis , Humans , Mice , Mice, Obese , Molecular Structure , Structure-Activity RelationshipABSTRACT
A new structural class of potent prolylcarboxypeptidase (PrCP) inhibitors was discovered by high-throughput screening. The series possesses a tractable SAR profile with sub-nanomolar in vitro IC(50) values. Compared to prior inhibitors, the new series demonstrated minimal activity shifts in pure plasma and complete ex vivo plasma target engagement in mouse plasma at the 20 h post-dose time point (po). In addition, the in vivo level of CNS and non-CNS drug exposure was measured.
Subject(s)
Carboxypeptidases/antagonists & inhibitors , Drug Discovery , Enzyme Inhibitors , Animals , Butanols/chemical synthesis , Butanols/chemistry , Butanols/pharmacology , Enzyme Activation/drug effects , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Inhibitory Concentration 50 , Male , Mice , Mice, Inbred C57BL , Molecular Structure , Obesity/drug therapy , Pyrrolidines/chemical synthesis , Pyrrolidines/chemistry , Pyrrolidines/pharmacologyABSTRACT
A series of potent inhibitors of prolylcarboxypeptidase (PrCP) was developed by modifying a lead structure that was discovered by high-throughput screening. The tert-butyl pyrrolidine was replaced by an aminocyclopentane to reduce the metabolic liabilities of the original lead. The compounds demonstrated sub-nanomolar in vitro IC(50) values, minimal activity shifts in pure plasma and improved pharmacokinetics. Complete ex vivo plasma target engagement was achieved with low brain exposure at the 20 h time point following p.o. dosing in a mouse. The results indicate that the aminocyclopentanes are useful tools for studying the therapeutic potential of peripheral (non-CNS) PrCP inhibition.
Subject(s)
Amines/pharmacology , Carboxypeptidases/antagonists & inhibitors , Cyclopentanes/pharmacology , Drug Discovery , Enzyme Inhibitors , Amines/chemical synthesis , Amines/chemistry , Animals , Cyclization , Cyclopentanes/chemical synthesis , Cyclopentanes/chemistry , Enzyme Activation/drug effects , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Inhibitory Concentration 50 , Male , Mice , Mice, Inbred C57BL , Molecular Structure , Obesity/drug therapyABSTRACT
Efforts were dedicated to develop potent and brain penetrant prolylcarboxypeptidase (PrCP) inhibitors by replacing the amide group of original leads 1 and 2 with heterocycles. Aminopyrimidines including compound 32a were identified to display good PrCP inhibitory activity (32a, IC(50)=43 nM) and impressive ability to penetrate brain in mice (brain/plasma ratio: 1.4).
Subject(s)
Amines/chemical synthesis , Brain/drug effects , Carboxypeptidases/antagonists & inhibitors , Drug Discovery , Enzyme Inhibitors , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/pharmacology , Amides/chemistry , Amines/chemistry , Amines/pharmacology , Animals , Brain/enzymology , Enzyme Activation/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Heterocyclic Compounds/chemistry , Inhibitory Concentration 50 , Mice , Molecular Structure , Structure-Activity RelationshipABSTRACT
CD8(+) cytotoxic T lymphocytes recognize infected cells in which MHC class I molecules present pathogen-derived peptides that have been processed mainly by proteasomes. Many infections induce a set of proteases, the caspases involved in apoptosis or inflammation. In this study, we report that processing and presentation of a short vaccinia virus-encoded Ag can take place also by a nonproteasomal pathway, which was blocked in infected cells with chemical inhibitors of caspases. By cleaving at noncanonical sites, at least two caspases generated antigenic peptides recognized by T lymphocytes. The sites and the peptidic products were partially overlapping but different to those used and produced by proteasomes in vitro. Antigenic natural peptides produced in infected cells by either pathway were quantitatively and qualitatively similar. Finally, coexpression of the natural vaccinia virus protein B13, which is an inhibitor of caspases and apoptosis, impaired Ag presentation by the caspase pathway in infected cells. These data support the hypothesis that numerous cellular proteolytic systems, including those induced during infection, such as caspases involved in apoptosis or in inflammation, contribute to the repertoire of presented peptides, thereby facilitating immunosurveillance.
Subject(s)
Antigen Presentation/immunology , CD8-Positive T-Lymphocytes/enzymology , CD8-Positive T-Lymphocytes/immunology , Caspases/physiology , Muromegalovirus/immunology , Vaccinia virus/immunology , Amino Acid Sequence , Animals , Apoptosis/immunology , CD8-Positive T-Lymphocytes/virology , Caspase Inhibitors , Caspases/metabolism , Cell Line , H-2 Antigens/metabolism , Histocompatibility Antigen H-2D , Immediate-Early Proteins/metabolism , Immunodominant Epitopes/metabolism , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Peptides/immunology , Peptides/metabolism , Proteasome Endopeptidase Complex/physiology , Signal Transduction/immunologyABSTRACT
A series of benzimidazole pyrrolidinyl amides containing a piperidinyl group were discovered as novel prolylcarboxypeptidase (PrCP) inhibitors. Low-nanomolar IC(50)'s were achieved for several analogs, of which compound 9b displayed modest ex vivo target engagement in eDIO mouse plasma. Compound 9b was also studied in vivo for its effect on weight loss and food intake in an eDIO mouse model and the results will be discussed.
Subject(s)
Amides , Benzimidazoles , Carboxypeptidases/antagonists & inhibitors , Drug Discovery , Enzyme Inhibitors , Pyrrolidines , Amides/chemistry , Amides/pharmacology , Animals , Benzimidazoles/chemistry , Benzimidazoles/pharmacology , Disease Models, Animal , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Humans , Inhibitory Concentration 50 , Mice , Molecular Structure , Pyrrolidines/chemistry , Pyrrolidines/pharmacology , Structure-Activity RelationshipABSTRACT
Lung fibrosis, or the scarring of the lung, is a devastating disease with huge unmet medical need. There are limited treatment options and its prognosis is worse than most types of cancer. We previously discovered that MK-0429 is an equipotent pan-inhibitor of αv integrins that reduces proteinuria and kidney fibrosis in a preclinical model. In the present study, we further demonstrated that MK-0429 significantly inhibits fibrosis progression in a bleomycin-induced lung injury model. In search of newer integrin inhibitors for fibrosis, we characterized monoclonal antibodies discovered using Adimab's yeast display platform. We identified several potent neutralizing integrin antibodies with unique human and mouse cross-reactivity. Among these, Ab-31 blocked the binding of multiple αv integrins to their ligands with IC50s comparable to those of MK-0429. Furthermore, both MK-0429 and Ab-31 suppressed integrin-mediated cell adhesion and latent TGFß activation. In IPF patient lung fibroblasts, TGFß treatment induced profound αSMA expression in phenotypic imaging assays and Ab-31 demonstrated potent in vitro activity at inhibiting αSMA expression, suggesting that the integrin antibody is able to modulate TGFß action though mechanisms beyond the inhibition of latent TGFß activation. Together, our results highlight the potential to develop newer integrin therapeutics for the treatment of fibrotic lung diseases.
Subject(s)
Antibodies/metabolism , Fibroblasts/metabolism , Integrin alphaV/metabolism , Pulmonary Fibrosis/metabolism , Animals , Antibodies/immunology , Bleomycin , CHO Cells , Cells, Cultured , Cricetinae , Cricetulus , Fibroblasts/cytology , Humans , Integrin alphaV/immunology , Male , Mice, Inbred C57BL , Naphthyridines/pharmacology , Propionates/pharmacology , Protein Binding , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/prevention & controlABSTRACT
Prolylcarboxypeptidase (PRCP) is a serine protease that catalyzes the cleavage of C-terminal amino acids linked to proline in peptides. It is ubiquitously expressed and is involved in regulating blood pressure, proliferation, inflammation, angiogenesis, and weight maintenance. To identify the candidate proximal target engagement markers for PRCP inhibition in the central nervous system, we profiled the peptidome of human cerebrospinal fluid to look for PRCP substrates using a MS-based in vitro substrate profiling assay. These experiments identified a single peptide, with the sequence YPRPIHPA, as a novel substrate for PRCP in human cerebrospinal fluid. The peptide YPRPIHPA is from the extracellular portion of human endothelin B receptor-like protein 2.
Subject(s)
Carboxypeptidases/cerebrospinal fluid , Carboxypeptidases/metabolism , Peptides/cerebrospinal fluid , Peptides/metabolism , Amino Acid Sequence , Humans , Molecular Sequence Data , Sequence Alignment , Substrate SpecificityABSTRACT
Cholesteryl ester transfer protein (CETP) has been identified as a novel target for increasing HDL cholesterol levels. In this report, we describe the biochemical characterization of anacetrapib, a potent inhibitor of CETP. To better understand the mechanism by which anacetrapib inhibits CETP activity, its biochemical properties were compared with CETP inhibitors from distinct structural classes, including torcetrapib and dalcetrapib. Anacetrapib and torcetrapib inhibited CETP-mediated cholesteryl ester and triglyceride transfer with similar potencies, whereas dalcetrapib was a significantly less potent inhibitor. Inhibition of CETP by both anacetrapib and torcetrapib was not time dependent, whereas the potency of dalcetrapib significantly increased with extended preincubation. Anacetrapib, torcetrapib, and dalcetrapib compete with one another for binding CETP; however anacetrapib binds reversibly and dalcetrapib covalently to CETP. In addition, dalcetrapib was found to covalently label both human and mouse plasma proteins. Each CETP inhibitor induced tight binding of CETP to HDL, indicating that these inhibitors promote the formation of a complex between CETP and HDL, resulting in inhibition of CETP activity.
Subject(s)
Anticholesteremic Agents/chemistry , Cholesterol Ester Transfer Proteins/antagonists & inhibitors , Oxazolidinones/chemistry , Quinolines/chemistry , Sulfhydryl Compounds/chemistry , Amides , Animals , Anticholesteremic Agents/metabolism , Blood Proteins/metabolism , Esters , Humans , Mice , Molecular Structure , Oxazolidinones/metabolism , Quinolines/metabolism , Sulfhydryl Compounds/metabolismABSTRACT
Ezetimibe (Zetia®), a cholesterol-absorption inhibitor (CAI) approved by the FDA for the treatment of hypercholesterolemia, is believed to target the intestine protein Niemann-Pick C1-Like 1 (NPC1L1) or its pathway. A spiroimidazolidinone NPC1L1 inhibitor identified by virtual screening showed moderate binding activity but was not efficacious in an in vivo rodent model of cholesterol absorption. Synthesis of analogs established the structure-activity relationships for binding activity, and resulted in compounds with in vivo efficacy, including 24, which inhibited plasma cholesterol absorption by 67% in the mouse, thereby providing proof-of-concept that non-ß-lactams can be effective CAIs.